This segment focuses on the development and manufacturing of at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms. StemoniX, a subsidiary of Vyant Bio, collaborates with drug discovery organizations to test compounds in-house, create cell-based disease models, and operationalize custom human iPSC-derived disease models for high-throughput screening. The platforms are used to accelerate drug discovery and development, particularly for complex neurodevelopmental and neurodegenerative disorders. This segment's competitive advantage lies in its ability to provide physiologically relevant human cell models for drug testing. Future opportunities include expanding the platform's capabilities to cover a wider range of diseases and therapeutic areas, and forming strategic partnerships to enhance market reach. The segment's success is dependent on the ability to secure and maintain intellectual property rights and to comply with relevant regulatory requirements.

This segment, operated through the vivoPharm subsidiary, offers proprietary preclinical test systems to support clinical diagnostic offerings at early stages of drug development. vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings. The focus is on providing comprehensive preclinical data to pharmaceutical and biotechnology companies, and academic research centers. The segment's competitive advantage is its expertise in designing and executing preclinical studies that meet regulatory requirements. Future opportunities include expanding the range of services offered, such as offering more specialized testing services and expanding into new therapeutic areas. The segment's success is dependent on maintaining high standards of quality and compliance with regulatory guidelines, and building strong relationships with clients.